SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Making individualized drugs a reality · Study

ArticleShelves

ArticleMaking individualized drugs a reality

Huub Schellekens2017

OA

Articlegreen2017

Making individualized drugs a reality

Huub Schellekens · Mohammed Aldosari · H. Talsma · Enrico Mastrobattista

50 citations·0/0 files stored·Nature Biotechnology

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Pharmaceutical Economics and Policy Pharmacogenetics and Drug Metabolism Pharmaceutical studies and practices

Abstract

No abstract was published for this record.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 50 citations exist upstream.

References

2012Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group 2016Overspending driven by oversized single dose vials of cancer drugs 2014Towards a sustainable system of drug development

Cited by

2021We Cannot Win the Access to Medicines Struggle Using the Same Thinking That Causes the Chronic Access Crisis.

Related works

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

2018The Future of Precision Medicine: Potential Impacts for Health Technology Assessmentarticle · 1 shared reference 2019Cost-effectiveness of precision medicine: a scoping reviewreview · 1 shared reference 2020Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Grouparticle · 1 shared reference 2013Issues Surrounding the Health Economic Evaluation of Genomic Technologiesreview · 1 shared reference 2017A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung Cancerarticle · 1 shared reference 2014Concepts of ‘Personalization’ in Personalized Medicine: Implications for Economic Evaluationarticle · 1 shared reference

Details

Year2017

Typearticle

Published2017-06-01

VenueNature Biotechnology

ISSN-L0733-222X

Languageen

Citations50

Files0 public / 0

ShelfPharmaceutical Economics and Policy

Identifiers

doi10.1038/nbt.3888

openalex_workW2624319332

Links

Imported from OpenAlex (CC0) — nothing here is generated.